title: The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.
abstract: The clinical efficacy of opioid receptor antagonists for the treatment of opioid-induced constipation (OIC) is established. Peripherally selective antagonists are intended to provide OIC symptom relief without compromising the analgesic effects of centrally penetrant opioid agonists. We describe the in vitro profile of a novel opioid receptor antagonist, TD-1211, at recombinant (human μ and δ, and guinea pig κ) and rodent native opioid receptors. TD-1211 bound with high affinity to human recombinant μ and δ, and guinea pig κ receptors expressed in CHO-K1 cells (pK d = 9.7, 8.6, and 9.9, respectively). The in vitro receptor selectivity of TD-1211 (μ ≈ κ > δ) is similar to that for the peripherally-selective opioid receptor antagonist methylnaltrexone, but contrasts with the μ selectivity of alvimopan. Functionally, TD-1211 behaved as an antagonist at all three receptor types in both recombinant expression systems (pK b = 9.6, 8.8 and 9.5, at μ, δ, and κ, respectively) and rodent native tissue preparations (μ and κ pA2s = 10.1 and 8.8, respectively (guinea pig ileum), and δ pK b = 8.4 (hamster vas deferens)). TD-1211 displayed a high degree of selectivity for opioid receptors over a broad panel of cellular targets. These in vitro data justified investigation of the preclinical in vivo activity of TD-1211 (Armstrong et al., Naunyn-Schmiedeberg's Arch Pharm, 2013).
authors.affiliation: Department of Molecular and Cellular Biology, Theravance, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA. ptsuruda@theravance.com
authors.forename: Pamela R
authors.initials: PR
authors.lastname: Tsuruda
authors.forename: Ross G
authors.initials: RG
authors.lastname: Vickery
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Long
authors.forename: Scott R
authors.initials: SR
authors.lastname: Armstrong
authors.forename: David T
authors.initials: DT
authors.lastname: Beattie
mesh_terms: D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008647:Mesocricetus; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014326:Tropanes / Q000494:pharmacology*
chemical_list: C585268:3-(8-(2-(cyclohexylmethyl(2,3-dihydroxypropionyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)benzamide; D001549:Benzamides; D009292:Narcotic Antagonists; D010880:Piperidines; D000644:Quaternary Ammonium Compounds; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D014326:Tropanes; C032257:methylnaltrexone; D009271:Naltrexone; C419502:alvimopan
references.citation: J Opioid Manag. 2010 Nov-Dec;6(6):435-44
references.pmid: 21269005
references.citation: Semin Oncol. 2000 Feb;27(1):45-63
references.pmid: 10697021
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37
references.pmid: 18415081
references.citation: J Pharmacol Exp Ther. 2005 Jun;313(3):1136-49
references.pmid: 15701707
references.citation: Life Sci. 2005 Feb 11;76(13):1427-37
references.pmid: 15680308
references.citation: Pharmacol Ther. 1996;69(2):103-15
references.pmid: 8984506
references.citation: Curr Top Med Chem. 2008;8(13):1102-12
references.pmid: 18782006
references.citation: Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:3-16
references.pmid: 15357847
references.citation: Eur J Pharmacol. 1993 Sep 14;241(2-3):149-56
references.pmid: 7902288
references.citation: P T. 2010 Jan;35(1):44-9
references.pmid: 20182561
references.citation: Cancer Nurs. 1998 Aug;21(4):289-97
references.pmid: 9691512
references.citation: Anesth Analg. 2009 Jun;108(6):1811-22
references.pmid: 19448206
references.citation: Wien Klin Wochenschr. 1996;108(1):5-8
references.pmid: 8677660
references.citation: J Pharmacol Exp Ther. 1994 Feb;268(2):965-70
references.pmid: 8114012
references.citation: J Med Chem. 1994 Jul 8;37(14):2125-8
references.pmid: 8035418
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20
references.pmid: 17340127
references.citation: Drugs. 2003;63(7):649-71
references.pmid: 12656645
references.citation: Br J Pharmacol. 2012 Nov;167(5):1111-25
references.pmid: 22671931
references.citation: Mol Pharmacol. 2006 Mar;69(3):921-31
references.pmid: 16339845
references.citation: J Pharmacol Exp Ther. 1990 Sep;254(3):792-8
references.pmid: 1975621
references.citation: Ther Clin Risk Manag. 2005 Dec;1(4):279-97
references.pmid: 18360571
references.citation: Eur J Pharmacol. 2005 Sep 27;520(1-3):29-36
references.pmid: 16165125
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):544-52
references.pmid: 17267582
references.citation: J Pharmacol Exp Ther. 1994 Jul;270(1):386-91
references.pmid: 8035336
references.citation: Clin Pharmacol Ther. 1992 Jul;52(1):90-5
references.pmid: 1623695
references.citation: Core Evid. 2010 Jun 15;4:247-58
references.pmid: 20694079
references.citation: Pain. 1999 Jan;79(1):1-13
references.pmid: 9928770
references.citation: J Neurochem. 2001 Jun;77(6):1590-600
references.pmid: 11413242
references.citation: J Pain. 2009 Feb;10(2):113-30
references.pmid: 19187889
references.citation: Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:17-28
references.pmid: 15357848
references.citation: Neuroscience. 1987 May;21(2):595-602
references.pmid: 3039405
references.citation: Jpn J Pharmacol. 1998 Sep;78(1):83-6
references.pmid: 9804067
references.citation: Br J Pharmacol. 1994 Aug;112(4):1077-82
references.pmid: 7952866
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1982 Dec;321(3):218-22
references.pmid: 7155202
references.citation: Br J Pharmacol. 1981 Aug;73(4):859-66
references.pmid: 7196785
references.citation: Neuropharmacology. 1985 Nov;24(11):1011-7
references.pmid: 3001569
references.citation: Br J Pharmacol. 1995 Mar;114(6):1206-10
references.pmid: 7620710
references.citation: Life Sci. 1994;54(20):PL339-50
references.pmid: 7514710
references.citation: J Pain Symptom Manage. 1990 Dec;5(6):362-7
references.pmid: 1980127
references.citation: J Physiol Paris. 2000 Mar-Apr;94(2):135-8
references.pmid: 10791695
references.citation: Am J Surg. 2001 Nov;182(5A Suppl):11S-18S
references.pmid: 11755892
references.citation: Drugs. 2012 Oct 1;72(14):1847-65
references.pmid: 22950533
references.citation: Jpn J Pharmacol. 1998 Aug;77(4):279-86
references.pmid: 9749928
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581
references.citation: Br J Pharmacol Chemother. 1968 Jun;33(2):266-76
references.pmid: 5664147
references.citation: Br J Pharmacol Chemother. 1959 Mar;14(1):48-58
references.pmid: 13651579
references.citation: Neurosurgery. 1995 Sep;37(3):422-8; discussion 428-9
references.pmid: 7501106
references.citation: Pain. 2000 Jan;84(1):105-109
references.pmid: 10601678
references.citation: Br J Pharmacol. 1981 Aug;73(4):921-32
references.pmid: 7196786
references.citation: Life Sci. 1995;56(14):1187-92
references.pmid: 7475895